Lexaria Bioscience Corp. LEXX
Lexaria Bioscience Corp. is a biotechnology company dedicated to the enhancement of the bioavailability of a diverse and broad range of active pharmaceutical ingredients ("APIs") using our patented DehydraTECHTM drug delivery technology. DehydraTECH combines APIs with specific long-chain fatty acid-rich triglyceride oils and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing for improved tolerability while promoting healthier oral ingestion methods.
DehydraTECH can be used with a wide range of active molecules including glucagon-like peptide-1 drugs ("GLP-1") and glucose-dependent insulinotropic polypeptide drugs ("GIP"), vitamins, pain medications, hormones, antivirals, nicotine and its analogs, and cannabinoids. Our technology can be applied to a variety of therapeutic indications, including diabetes, weight loss, epilepsy, hypertension and heart disease. DehydraTECH can be implemented in a multitude of ingestible product formats including oral suspensions, tablets, capsules, foods, beverages, and oral pouches. It is suitable for use with a variety of product formats including pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $705.9K | $464.3K | $226.2K | $255.4K | $722.7K | $314.8K | $222.6K | $433.3K | $63.6K | $40.7K |
| Cost of revenue | $2.7K | $4.8K | $31.5K | $71.8K | $175.3K | $99.4K | $22.9K | $25.2K | $29.8K | $45.6K |
| Gross profit | $703.2K | $459.5K | $194.7K | $183.6K | $547.4K | $215.4K | $199.7K | $408.1K | $33.9K | -$4.9K |
| R&D | $8.2M | $2.4M | $3.7M | $1.8M | $1.3M | $387.1K | $555.7K | $492.9K | $54.2K | $9.0K |
| SG&A | $4.3M | $3.9M | $3.1M | $5.0M | $5.0M | $4.0M | $297.2K | $217.7K | $129.7K | $133.7K |
| Total operating expenses | $12.6M | $6.2M | $6.7M | $6.8M | $6.2M | $4.4M | $4.4M | $7.0M | $2.0M | $1.3M |
| Operating income | -$11.9M | -$5.8M | -$6.5M | -$6.6M | -$5.7M | — | — | — | — | -$1.3M |
| Interest expense | — | $14.3K | $43.2K | — | — | — | — | — | $6.0K | $2.2K |
| Pre-tax income | -$11.9M | -$5.8M | -$6.7M | -$7.4M | -$4.2M | -$4.0M | -$4.2M | -$6.6M | -$1.9M | -$1.3M |
| Income tax | — | — | — | $0 | $6.1K | $2.3K | $17.7K | $0 | $0 | $0 |
| Net income | -$11.9M | -$5.8M | -$6.7M | -$7.3M | -$4.0M | -$4.1M | -$4.2M | -$6.6M | -$1.9M | -$1.3M |
| EPS, diluted | -0.66 | -0.47 | -1.01 | — | -0.95 | -1.47 | -0.05 | -0.09 | -0.03 | -0.03 |
| Shares, diluted (wtd. avg.) | 18.0M | 12.4M | 6.6M | — | — | — | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $1.8M | $6.5M | $1.4M | $5.8M | $10.9M | $1.3M | $1.3M | $1.7M | $2.5M | $93.4K |
| Short-term investments | $22.1K | $55.8K | $125.6K | $347.3K | $833.8K | $19.3K | $64.2K | $10.2K | — | — |
| Receivables | $368.4K | $154.5K | $126.7K | $201.8K | $342.4K | $313.9K | $273.1K | $265.8K | $45.3K | $131.1K |
| Inventory | — | — | $0 | $38.4K | $29.6K | $116.9K | $127.4K | $87.2K | $67.2K | $134.7K |
| Total current assets | $3.5M | $7.9M | $2.2M | $7.0M | $12.4M | $1.9M | $1.8M | $2.3M | $2.8M | $510.2K |
| Property, plant and equipment | $228.1K | $254.7K | $254.1K | $315.5K | $368.2K | $483.4K | $591.3K | $1.2K | $1.9K | $2.5K |
| Other intangibles | $307.8K | $516.7K | $462.6K | — | — | $292.0K | $265.1K | $146.5K | $62.8K | $54.0K |
| Total assets | $4.2M | $8.9M | $3.1M | $7.8M | $13.3M | $2.8M | $2.7M | $2.4M | $2.9M | $566.6K |
| Accounts payable | $1.5M | $1.1M | $239.9K | $151.4K | $105.5K | $86.9K | $136.4K | $35.8K | $32.6K | $90.0K |
| Total current liabilities | $1.5M | $1.1M | $267.7K | $194.0K | $153.3K | $225.9K | $184.5K | $43.6K | $92.3K | $433.9K |
| Total liabilities | $1.6M | $1.2M | $403.9K | $201.4K | $203.3K | $346.0K | $184.5K | $43.6K | $92.3K | $478.9K |
| Retained earnings | -$63.5M | -$51.6M | -$45.8M | -$39.1M | -$31.8M | -$27.8M | -$23.9M | -$19.8M | -$13.2M | -$11.3M |
| Total equity | $3.0M | $8.0M | $2.7M | $7.6M | $13.1M | $2.5M | $2.5M | $2.4M | $2.8M | $87.8K |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$10.5M | -$5.0M | -$5.9M | -$4.9M | -$4.0M | -$2.6M | -$3.0M | -$2.5M | -$1.5M | -$660.9K |
| Depreciation and amortisation | $51.2K | $42.4K | — | — | $111.7K | $112.8K | $60.5K | $2.3K | $1.5K | $619 |
| Stock-based compensation | $859.5K | $492.2K | $170.4K | $752.6K | $410.0K | — | — | — | — | $122.0K |
| Capital expenditure | $24.6K | $43.0K | $33.7K | $49.2K | — | $0 | $646.2K | — | $0 | $3.1K |
| Investing cash flow | -$243.0K | -$188.6K | -$169.6K | -$180.6K | $193.9K | -$26.8K | -$769.2K | -$155.4K | -$9.7K | -$20.1K |
| Financing cash flow | $6.0M | $10.3M | $1.6M | -$44.6K | $13.4M | $2.7M | $3.3M | $1.9M | $4.0M | $514.3K |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001640334-25-002225.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $40.7K | $63.6K | $433.3K | $222.6K | $314.8K | $722.7K | $255.4K | $226.2K | $464.3K | $705.9K |
| Gross profit | -$4.9K | $33.9K | $408.1K | $199.7K | $215.4K | $547.4K | $183.6K | $194.7K | $459.5K | $703.2K |
| Net income | -$1.3M | -$1.9M | -$6.6M | -$4.2M | -$4.1M | -$4.0M | -$7.3M | -$6.7M | -$5.8M | -$11.9M |
Recent filings and events
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Other event Item 8.01
- Delisting notice The exchange has told the company it no longer meets the rules for staying listed - usually price, market cap, or filings that are late. Item 3.01
- Shareholder rights changed The terms attaching to the shares themselves have changed. Item 3.03
- Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
- Delisting notice Item 3.01
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
- Other event Item 8.01
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Material agreement signed Item 1.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |